Journal of Medicinal Chemistry
Article
Methylated Cyclic Pentaalanine Peptides as Template Structures. J.
Am. Chem. Soc. 2006, 128, 15164−15172.
emptying and meal-related symptoms in idiopathic gastroparesis.
Aliment. Pharmacol. Ther. 2005, 22, 847−853. (c) Murray, C. D.;
Martin, N. M.; Patterson, M.; Taylor, S. A.; Ghatei, M. A.; Kamm, M.
A.; Johnston, C.; Bloom, S. R.; Emmanuel, A. V. Ghrelin enhances
gastric emptying in diabetic gastroparesis: a double blind, placebo
controlled, crossover study. Gut 2005, 54, 1693−1698.
(18) (a) Fraser, G. L.; Venkova, K.; Hoveyda, H. R.; Thomas, H.;
Greenwood-Van Meerveld, B. Effect of the ghrelin receptor agonist
TZP-101 on colonic transit in a rat model of postoperative ileus. Eur. J.
Pharmacol. 2009, 604, 132−137. (b) Lasseter, K. C.; Shaughnessy, L.;
Cummings, D.; Pezzullo, J. C.; et al. Ghrelin agonist (TZP-101):
Safety, pharmacokinetics and pharmacodynamic evaluation in healthy
volunteers: A phase I, first-in-human study. J. Clin. Pharm. 2008, 48,
193−202. (c) Venkova, K.; Fraser, G.; Hoveyda, H. R.; Greenwood-
Van Meerveld, B. Prokinetic effects of a new ghrelin receptor agonist
TZP-101 in a rat model of postoperative ileus. Dig. Dis. Sci. 2007, 52,
2241−2248.
(6) Hoffmann, R. W. Conformation design of open-chain
compounds. Angew. Chem., Int. Ed. 2000, 39, 2054−2070.
(7) Veber, D. F.; Johnson, S. R.; Cheng, H. Y.; Smith, B. R.; Ward, K.
W.; Kopple, K. D. Molecular properties that influence the oral
bioavailability of drug candidates. J. Med. Chem. 2002, 45, 2615−2623.
(8) Marsault, E.; Hoveyda, H. R.; Gagnon, R; Peterson, M. L.;
́
Vezina, M.; Saint-Louis, C.; Landry, A.; Pinault, J.-F.; Ouellet, L.;
Beauchemin, S.; Beaubien, S.; Mathieu, A.; Benakli, K.; Wang, Z.;
Brassard, M.; Lonergan, D.; Bilodeau, F.; Ramaseshan, M.; Fortin, N.;
Lan, R.; Li, S.; Galaud, F.; Plourde, V.; Champagne, M.; Doucet, A.;
Bher
́
er, P.; Gauthier, M.; Olsen, G.; Villeneuve, G.; Bhat, S.; Foucher,
iel, R.;
L.; Fortin, D.; Peng, X.; Bernard, S.; Drouin, A.; Dez
́
Berthiaume, G.; Dory, Y. L.; Fraser, G. L.; Deslongchamps, P.
Efficient parallel synthesis of macrocyclic peptidomimetics. Biorg. Med.
Chem. Lett. 2008, 18, 4731−4735.
(9) For some recent reviews, see: (a) Driggers, E. M.; Hale, S. P.;
Lee, J.; Terrett, N. K. The exploration of macrocycles for drug
discoveryan underexploited structural class. Nature Rev. Drug
Discovery 2008, 7, 608−624. (b) Marsault, E. M.; Peterson, M. L.
Macrocycles are Great Cycles: Applications, Opportunities, and
Challenges of Synthetic Macrocycles in Drug Discovery. J. Med.
Chem. 2011, 54, 1961−2004.
(19) (a) Popescu, I.; Fleshner, P. R.; Pezzullo, J. C.; Charlton, P. A.;
Kosutic, G.; Senagore, A. J. The Ghrelin Agonist TZP-101 for
Management of Postoperative Ileus After Partial Colectomy: A
Randomized, Dose-Ranging, Placebo-Controlled Clinical Trial. Dis.
Colon Rectum 2010, 53, 126−134. (b) Ejskjaer, N.; Dimcevski, G.; Wo,
J.; Hellstrom, P. M; Gormsen, L. C.; Sarosiek, I.; Søfteland, E.; Nowak,
̈
T.; Pezzullo, J. C.; Shaughnessy, L.; Kosutic, G.; McCallum, R. Safety
and efficacy of ghrelin agonist TZP-101 in relieving symptoms in
patients with diabetic gastroparesis: a randomized, placebo-controlled
study. Neurogastroenterol. Motil. 2010, 22, 1069−1078. (c) Wo, J. M.;
(10) Marsault, E.; Hoveyda, H. R.; Peterson, M. L.; Saint-Louis, C.;
Landry, A.; Vez
Beaubien, S.; Benakli, K.; Beauchemin, S.; Dez
́
ina, M.; Ouellet, L.; Wang, Z.; Ramaseshan, M.;
iel, R.; Peeters, T.;
́
Fraser, G. L. Discovery of new class of macrocyclic antagonists to the
human motilin receptor. J. Med. Chem. 2006, 49, 7190−7197.
(11) Kojima, M.; Hosoda, H.; Date, Y.; Nakazato, M.; Matsuo, H.;
Kangawa, K. Ghrelin is a growth- hormone-releasing acylated peptide
from stomach. Nature 1999, 402, 656−660, Ghrelin amino acid
s e q u e n c e i s a s f o l l o w s : G S S ( n - o c t a n o y l )
FLSPEHQRVQQRKESKKPPAKLQPR. The octanoylated ghrelin
peptide was used throughout the work herein..
Ejskjaer, N.; Hellstrom, P. M.; Malik, R. A.; Pezzullo, J. C.;
̈
Shaughnessy, L.; Charlton, P.; Kosutic, G.; McCallum, R. W.
Randomised clinical trial: ghrelin agonist TZP-101 relieves
gastroparesis associated with severe nausea and vomiting
randomised clinical study subset data. Aliment. Pharmacol. Ther.
2011, 33, 679−688.
(20) Fraser, G. L.; Hoveyda, H. R.; Tannenbaum, G. S.
Pharmacological Demarcation of the Growth Hormone, Gut
Motility and Feeding Effects of Ghrelin Using a Novel Ghrelin
Receptor Agonist. Endocrinology 2008, 149, 6280−6288.
(21) For further comparison of the GH and GI effects of GRLN
agonists in development for GI disorders, see: (a) Charoenthongtrakul,
S.; Giuliana, D.; Longo, K. A.; Govek, E. K.; Nolan, A.; Gagne, S.;
(12) Davenport, A. P.; Bonner, T. I.; Foord, S. M.; Harmar, A. J.;
Neubig, R. R.; Pin, J.-P.; Spedding, M.; Kojima, M.; Kangawa, K.
International Union of Pharmacology. LVI. Ghrelin Receptor
Nomenclature, Distribution, and Function. Pharmacol. Rev. 2005, 57,
541−546.
(13) Exemplified by this subclass are receptors such as GnRH,
galanin, MCH, orexin, a number of chemokine receptors that are
variously involved in obesity, eating and reproductive disorders, pain,
inflammation and narcolepsy. See: Lavrador, K.; Murphy, B.; Saunders,
J.; Struthers, S.; Wang, X.; Williams, J. A screening library for peptide
activated G-protein coupled receptors. 1. The test set. J. Med. Chem.
2004, 47, 6864−6874.
́
Morgan, K.; Hixon, J.; Flynn, N.; Murphy, B. J.; Hernandez, A. S.; Li,
J.; Tino, J. A.; Gordon, D. A.; DiStefano, P. S.; Geddes, B. J. Enhanced
gastrointestinal motility with orally active ghrelin receptor agonists. J.
Pharmacol. Exp. Ther. 2009, 329, 1178−1186. (b) Garcia, J. M.;
Polvino, W. J. Pharmacodynamic hormonal effects of of anamorelin, a
novel oral ghrelin mimetic and growth hormone secretagogue in
human volunteers. Growth Horm. IGF Res. 2009, 19, 267−273.
(c) Datta, R.; Soulard, C.; Teillot, M.; Touvay, C.; Halem H.; Dong, J.
Z.; Culler, M. D. RM-131: a potent gastroprokinetic agent.
Gastroenterology 2011, 140(5), Suppl 1, S-25. (d) Pietra, C.; Friend,
J.; Greenwoord-van Meerveld, B. Preclinical pharmacological profile of
ipamorelin a novel gastroprokinetic for intestinal dysmotility.
Gastroenterology 2011, 140(5), Suppl 1, S-285.
(14) Howard, A. D.; Feighner, S. D.; Cully, D. F.; Arena, J. P.;
Liberator, P. A.; Rosenblum, C. I.; Hamelin, M.; Hreniuk, D. L.;
Palyha, O. C.; Andrerson, J.; Paress, P. S.; Diaz, C.; Chou, M.; Liu, K.
K.; McKee, K. K.; Pong, S.-S.; Chaung, L.-Y.; Elbrecht, A.; Dashkevicz,
M.; Heavens, R.; Rigby, M.; Sirinathsighji, D. J. S.; Dean, D. C.;
Melillo, D. G.; Patchett, A. A.; Nargund, R.; Griffin, P. R.; DeMartino,
J. A.; Gupta, S. K.; Schaeffer, J. M.; Smith, R. G.; Van der Ploeg, L. H.
T. A receptor in pituitary and hypothalamus that functions in growth
hormone release. Science 1996, 273, 974−977.
(22) For some recent reviews, see: (a) Moulin, A.; Ryan, J.; Martinez,
J.; Fehrentz, J.-M. Recent Developments in Ghrelin Receptor Ligands.
ChemMedChem 2007, 2, 1242−1257. (b) Costantino, L.; Barlocca, D.
Ghrelin receptor modulators and their therapeutic potential. Fut. Med.
Chem. 2009, 1, 157−177.
(15) Peeters, T. L. Ghrelin: A new player in the control of
gastrointestinal functions. Gut 2006, 54, 1638−1649, and references
therein.
(23) Holst, B.; Brandt, E.; Bach, A.; Heding, A.; Schwartz, T. W.
Nonpeptide and peptide growth hormone secretagogues act both as
ghrelin receptor agonist and as positive or negative allosteric
modulators of ghrelin signaling. Mol. Endocrinol. 2005, 19, 2400−2411.
(24) The ligand activation domain of GRLN is highly conserved
across species and is most closely homologous to the MOT-R, which is
52% identical to GRLN with 86% identity in the transmembrane
domains. See: Coulie, B.; Matsuura, B.; Dong, M.; Hadac, E. M.;
Pinon, D. I.; Feighner, S. D.; Howard, A. D.; Miller, L. J. Identification
of peptide ligand-binding domains within the human motilin receptor
(16) Levin, F.; Edholm, T.; Schmidt, P. T.; Gryback, P.; Jacobsson,
̈
H; Degerblad, C.; Hoybye, C.; Holst, J. J.; Rehfeld, J. F.; Hellstrom, P.
̈
̈
M.; Naslund, E. Ghrelin stimulates gastric emptying and hunger in
̈
normal weight humans. J. Clin. Endocrinol. Metab. 2006, 91, 3279−
3280.
(17) (a) Binn, M.; Albert, C.; Gougeon, A.; Maerki, H.; Coulie, B.;
Lemoyne, M.; Rabasa Lhoret, R.; Tomasetto, C.; Poitras, P. Ghrelin
gastrokinetic action in patients with neurogenic gastroparesis. Peptides
2006, 27, 1603−1606. (b) Tack, J.; Depoortere, I.; Bisschops, R.;
Verbeke, K.; Janssens, J.; Peeters, T. Influence of ghrelin on gastric
8318
dx.doi.org/10.1021/jm2007062 | J. Med. Chem. 2011, 54, 8305−8320